Reimbursed Care Access in Syrian Arab Republic

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Syria is party to the 1971 Convention on Psychotropic Substances and the 1961 Single Convention, and its domestic narcotics legislation applies severe penalties for unauthorized possession, trafficking or manufacture of psychotropic substances. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Syria’s narcotics code criminalizes possession, supply and trafficking of psychotropic substances and provides for severe penalties for illicit activity. # #.

Esketamine (the marketed intranasal product Spravato) does not appear in publicly available Syrian regulatory listings or published approvals; there is no evidence of a national reimbursement pathway or structured program for esketamine in Syria. Syria’s health system relies on the Ministry of Health for registration and importation of medicines and on narcotics control mechanisms for overseeing controlled drugs; however, public documentation of an esketamine marketing authorization or public insurance coverage in Syria was not found in open sources. Given Syria’s stringent controls on psychotropic and narcotic substances and the lack of evidence of local approval, access would likely require special import authorization (if permitted) and would not be part of routine reimbursed care. For regional context on anesthetic/psychoactive product listings in nearby country formularies (not Syria-specific), see an example Lebanese Ministry of Public Health medicines listing (shows Spravato entries for Lebanon only). # #.

Ketamine is an established anesthetic and analgesic in Syrian clinical practice but supply and procurement are tightly controlled and at times unreliable. Multiple humanitarian and health-system reports note ketamine’s use for surgical and obstetric anesthesia in Syria, while also documenting procurement restrictions and reliance on informal/black‑market sources in some conflict-affected areas when formal supply chains were disrupted. This indicates that ketamine has recognized medical use (administered in hospitals and clinics) but that institutional procurement and distribution are constrained by regulatory controls, conflict-related supply challenges, and counter‑narcotics enforcement. Syria’s narcotics legislation governs controlled substances and imposes strict penalties for diversion or illicit distribution; medical use of ketamine therefore occurs within a tightly regulated system overseen by national health and law‑enforcement authorities. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. As a party to the 1971 Convention on Psychotropic Substances, Syria’s domestic law criminalizes unauthorized handling of DMT. No public evidence of authorized clinical programs or reimbursement pathways for DMT-derived therapies in Syria was identified. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. No public mechanism for medical access or reimbursement for 5‑MeO‑DMT in Syria was found in open-source materials. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no documentation of licensed ibogaine treatment centers, regulatory approvals, or reimbursement in Syria. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws when containing DMT; plant‑based brews containing DMT are not permitted outside approved research. No authorized ceremonial or therapeutic use pathways for ayahuasca were identified in Syria. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline and mescaline‑containing cacti (except where explicitly exempted by law) are regulated under Syria’s implementation of international psychotropic substance controls; no medical programs or reimbursement pathways were identified. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Novel phenethylamine derivatives (including 2C-series compounds) are covered by Syria’s broad psychotropic and narcotics controls and are subject to enforcement; no legal medical access or reimbursement pathways exist. # #.